High materiality7/10
ResMed (RMD) PT Lowered to $300 at UBS
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS lowers ResMed's price target to $300.
- UBS lowers RMD PT to $300
Key facts
- 01
Target: $300
- 02
Posted price: $195.97
- 03
Analyst firm: UBS
- 04
Analyst: David Low
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.